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Aims Monocytes play critical roles in tissue injury and repair following acutemyocardial infarction (AMI). Specifically targeting
inflammatorymonocytes in experimentalmodels leads to reduced infarct size and improved healing.However, data from
humans are sparse, and it remains unclear whether monocytes play an equally important role in humans. The aim of this
study was to investigate whether the monocyte response following AMI is conserved between humans and mice and in-
terrogate patterns of gene expression to identify regulated functions.
Methods
and results
Thirty patients (AMI) and 24 control patients (stable coronary atherosclerosis) were enrolled. Female C57BL/6J mice
(n ¼ 6/group) underwent AMI by surgical coronary ligation. Myocardial injury was quantified by magnetic resonance
imaging (human) and echocardiography (mice). Peripheral monocytes were isolated at presentation and at 48 h. RNA
fromseparatedmonocyteswas hybridized to Illumina beadchips.Acutemyocardial infarction resulted in a significant per-
ipheral monocytosis in both species that positively correlatedwith the extent ofmyocardial injury. Analysis of themono-
cyte transcriptome following AMI demonstrated significant conservation and identified inflammation and mitosis as
central processes to this response. These findings were validated in both species.
Conclusions Our findings show that the monocyte transcriptome is conserved between mice and humans following AMI. Patterns of
gene expression associated with inflammation and proliferation appear to be switched on prior to their infiltration of
injured myocardium suggesting that the specific targeting of inflammatory and proliferative processes in these immune
cells in humans are possible therapeutic strategies. Importantly, they could be effective in the hours after AMI.
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Translational perspective
The immune systemplays critical roles inmyocardial injury and repair following acutemyocardial infarction (AMI). Evidence fromexperimen-
talmodels strongly implicatesmonocytes as critical to theseprocesses and their specific targeting results in a significant reduction in infarct size
and improved healing. It is currently unclear if monocytes play a similarly important role in humans. Examining changes in the patterns of gene
expression can address this question. Here, we show that the peripheral blood monocyte response following AMI is conserved between
species and that monocytes appear to be ‘programmed’ prior to their arrival at sites of myocardial injury. This investigation may translate
to the future development of therapeutics to treat patients presenting with AMI that importantly would be effective in the hours after the
onset of ischaemia.
Introduction
In AMI, irreversible tissue injury occurs due to sustained ischaemia. In
addition, recent pivotal studies have shown that the innate immune
system is activated in AMI, sequentially mediating aspects of both
injury and repair.1–3 Importantly, early phase monocytes appear
to act asmediators of injury, since attenuating the response of inflam-
matory monocytes with siRNA,4,5 angiotensin converting enzyme
inhibitors,6 or splenectomy6 significantly reduced infarct size in ex-
perimental models.4–6 These processes have been studied in great
detail in mice5–8 but analogous data from humans are sparse9,10
and it is therefore not clear if monocytes in humans are equally im-
portant in comparison with experimental models.
In fact, for both humans and mice, characterization of the mono-
cyte response following AMI has largely relied on the analysis of a
very limited repertoire of cell surface proteins.11,12 In mice, mono-
cytes are functionally and phenotypically heterogeneous and can
be divided into subsets by the presence of the cell surface protein
Ly6C. Ly6Chi monocytes express high levels of CCR2 and accumu-
late preferentially in inflammatory sites.11 These can be distinguished
from Ly6Clo monocytes, which patrol the vasculature13 and have
roles in tissue repair and angiogenesis.7 Following AMI in mice, and
possibly humans,10,14 monocytes from the spleen15 and the bone
marrow16 are recruited to ischaemic myocardium via the blood in
a coordinated manner.9 In mice, Ly6Chi monocytes are mobilized
early, peaking in blood at48 h. There is also monocyte heterogen-
eity in humans, with analogous subsets based on the cell surface
protein expression of CD14 and CD16.12 CD14++CD162 resem-
ble Ly6Chi monocytes, whilst CD14dimCD16+monocytes resemble
Ly6Clo monocytes in mice.
Whilst cell surface proteins distinguish monocyte subsets in mice
and humans, are of descriptive value and are widely used, they
provide little functional insight. In contrast, whole-genome expres-
sion profiling in leukocytes provides an opportunity for unbiased
analysis of cellular function and therefore of the characterization of
pathways and processes with far greater complexity than can be
attained using only surface markers.17–19 Accordingly, we quantify
changes in the transcriptome of monocytes isolated from peripheral
blood early after AMI, as well as in absolute monocyte numbers (and
their subsets).
Mouse models can be highly informative and have enabled
increased understanding in the pathogenesis of AMI. However, cau-
tionary experience from other models argues that they cannot be
assumed to be representative of human disease.20,21 By comparing
changes in the monocyte transcriptome following AMI in mice and
humans, we evaluate whether there is a conserved response
between species, thereby contributing to the validation of mouse
models for the study of disease mechanisms and therapies in this
domain. Furthermore, we use gene set enrichment analysis (GSEA)
to determine and understand the functional relevance of these
responses, which we confirm at protein level, thereby identifying
new possibilities for patient stratification and targeted therapies
post AMI.
Materials and methods
Ethics statement
Animal studies were undertaken with the approval of the University of
Oxford Ethical Review Committee and procedures were conducted in
accordance with the UK Home Office Animals (Science Procedures)
Act 1986 (HMSO UK) incorporating European directive 2010/63/EU.
The clinical studyprotocolswere approvedby theOxfordshireResearch
Ethics Committee (references 08/H0603/41 and 11/SC/0397). All
patients provided informed consent to participate.
Mouse model of acute myocardial infarction
All experiments were conducted on female C57BL/6J mice (Harlan,
Blackthorn, UK) at 24 weeks of age (n ¼ 6/group) due to the higher inci-
dence of acute ventricular rupture in male mice.22 Surgical AMI was
induced as previously described.23 Sham-procedure mice underwent
the same protocol, but without ligation of the coronary artery. Trans-
thoracic echocardiography (TTE)was carriedoutwith aVevo2100ultra-
sound system (Visualsonics, Amsterdam, The Netherlands) 48 h after
AMI and fractional shortening was used to quantify infarct size of infarct.
Human subjects
Thirty consecutive patients presenting to the Oxford Heart Centre with
STEMIwere recruited between June 2012 andNovember 2012 as part of
the Oxford acute myocardial infarction (OxAMI) study. Peripheral
venous blood was obtained from patients at presentation (the ‘hypera-
cute’ time point—before primary angioplasty and during AMI) and at
48 h following presentation (48 h time point) and processed within
30 min. Additionally, 24 stable patients,with confirmed coronary athero-
sclerosis were recruited to act as controls (Table 1).
All patients (n ¼ 30) underwent 3 Tesla cardiac magnetic resonance
(CMR; Verio, Siemens, Germany) within 48 h of presentation and 23
patients underwent a second CMR scan at 6 months. Both CMR scans
assessed left ventricular function (LVF), oedema, and late gadolinium
enhancement (LGE) as previously described24 (Supplementary material
online, Table S2). Cardiac magnetic resonance analysis was carried out
using cmr42w software (Circle Cardiovascular Imaging Inc., Calgary,
Canada).
N. Ruparelia et al.1924
Flow cytometry
All stained sampleswere analysed using the flow cytometer (CyANADP
Flow cytometer, Dako, Ely, UK). Data were analysed using FlowJo soft-
ware, version 7.6.3 (Tree Star Inc., OR, USA).
Mice
Whole blood was obtained (n ¼ 6/group) and cell suspensions
were prepared as previously described25 and were incubated with
the following antibodies: CD11b-APC, Ly6G-PE, Ly6C-FITC (all BD
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Table 1 Patient demographic data
CONTROL STEMI P-value
n 24 30 n/a
M:F 18:6 27:3 P ¼ 0.71
Age (mean, range) 63.4 (46–79) 60.1 (38–87) P ¼ 0.64
CV risk
Diabetes mellitus 3 (12.5%) 4 (13.3%) P ¼ 0.81
Smoker 13 (54.2%) 19 (63.3%) P ¼ 0.42
Hypertension 21 (87.5%) 10 (33.3%) P, 0.001
Hypercholesterolaemia 10 (41.7%) 4 (13.3%) P, 0.001
Family history 10 (41.7%) 12 (40%) P ¼ 0.53
Previous stroke/AMI 11 (45.8%) 0 (0%) P, 0.001
Lipoproteins (mmol/L) (mean, SD)
Total cholesterol 4.14 (1.09) 4.74 (0.87) P ¼ 0.77
LDL-c 2.2 (0.82) 3.1 (1.23) P ¼ 0.26
HDL-c 1.09 (0.29) 1.07 (0.3) P ¼ 0.89
TG 1.78 (0.85) 1.5 (1.28) P ¼ 0.19
Admission medication
Aspirin n/a 1 (3.3%) n/a
Clopidogrel/prasugrel n/a 0 (0%) n/a
b-Blocker n/a 2 (6.7%) n/a
ACE-I/ARB n/a 5 (16.7%) n/a
Statin n/a 4 (13.3%) n/a
Calcium blocker n/a 5 (16.7%) n/a
Diuretic n/a 1 (3.3%) n/a
Renal function (mean, SD)
Creatinine (mmol/L) 85.54 (19) 82.23 (14.95) P ¼ 0.24
Infarct-related artery
Left main stem n/a 0 (0%) n/a
Left anterior descending n/a 14 (46.7%) n/a
Circumflex n/a 4 (13.3%) n/a
Right coronary artery n/a 12 (40%) n/a
Peri-procedural medication
Bivalirudin n/a 30 (100%) n/a
Heparin n/a 16 (53.3%) n/a
Glycoprotein IIb/IIIa inhibitor n/a 0 (0%) n/a
Revascularization time (min)
Call-to-balloon n/a 119.4 (47.93) n/a
Door-to-balloon n/a 35.48 (32.25) n/a
Discharge medication
Aspirin 24 (100%) 30 (100%) P ¼ 1.0
Clopidogrel/prasugrel 10 (41.7%) 30 (100%) P, 0.001
b-Blocker 17 (70.8%) 29 (96.7%) P, 0.01
ACE-I/ARB 18 (75%) 29 (96.7%) P, 0.01
Statin 17 (70.8%) 30 (100%) P, 0.01
Calcium blocker 7 (29%) 0 (0%) P, 0.001
Diuretic 3 (12.5%) 4 (13.3%) P ¼ 0.93
STEMI, ST-segment elevation myocardial infarction; n, number; M, male; F, female; CV, cardiovascular; LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein
cholesterol; TG, triglycerides; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
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Pharmingen, Oxford, UK), and CD115-PerCP (eBioscience, San
Diego, USA).
Human
Whole venous blood was stained with the following antibodies:
CD14-APC, CD16-PE-Cy7, CD86-PE, CD42b-FITC, CD11b-Pacific
Blue, CD66b-PE-Cy5, CD56-PE-Cy5, CD123-PE-Cy5 (all BD Pharmin-
gen), and TLR2-FITC (all BD Pharmingen) or permeabilized and stained
with Ki67-FITC (BD Pharmingen) for validation studies.
Monocyte cell sorting
Mousecell suspensionswere immediatelysortedonanMOFLOcell sorter
(Dako, Ely, UK). Human monocytes were isolated using the EasySep
Human monocyte enrichment kit without CD16 depletion (StemCell
Technologies, Grenoble, France) as per the manufacturer’s instructions.
Microarray
Extracted and purified RNA samples from individual samples with a 260/
280 . 2.0 andanRNA integritynumber.7.0 (Agilent,Wokingham,UK)
were deemed acceptable. Following amplification and biotin labelled,
mouse RNA was hybridized to Mouse WG-6 BeadChips (Illumina, San
Diego, CA, USA) and human RNA to Illumina Human HT12v3.0
BeadChips (Illumina).
Immunohistochemistry
Frozen sections of tissue harvested from mice were stained with CD11b
(BD Pharmingen, Oxford, UK) and Ki67 (Abcam, Cambridge, UK). Five
randomFOVsat20×magnificationwere recorded (LeicaDM2500micro-
scope)and thenumberofcells positive forCD11bandKi67wereassessed.
Analysis of gene expression profiles
Microarray datawere analysed usingGenePattern (Broad Institute, Cam-
bridge,MA,USA).Differentially expressed geneswere identified using an
unpaired t-test with a fold change of.1.5 and a P, 0.05 deemed neces-
sary for significance. Gene-set enrichment analysis and leading-edge
analysis using the C7 collection of the molecular signature database
(MSIGDB; http://www.broadinstitute.org/gsea/msigdb) was performed
as previously described,26,27 a false discovery rate (FDR) , 0.25 was
deemed necessary for significance.
Gene set enrichment analysis
Gene set enrichment analysis yields a quantitative measure of the
over-representation of a set of genes (e.g. genes encoding products in
a same metabolic pathway) at the top or bottom of a ranked list of
genes. Candidate genes are ranked by their differential expression
between two phenotypes. The statistic is a weighted Kolmogorov–
Smirnov-like statistic and significance is calculated using an empirical
permutation test.28Hereweapplied anextendedversionof conventional
GSEA in order to produce an enrichment score in a single sample, as
described previously.29 Such a score is necessary in order to make a pre-
dictive call on single samples without reference to a larger group of
samples. In this approach, the genes areorderedbasedon either absolute
expression or the relative changes with respect to the baseline level.
Gene set enrichment analysis was performed as described previously.28
Gene sets enriching with FDR, 0.01 were used for leading-edge analysis
using Pearson correlation.30 Gene clusters were functionally annotated
by calculating overlap with GO terms using PANTHER algorithm31 on
AmiGO 2 version 2.1.3.32,33
Statistics
Values are expressed as mean+SD. The Gaussian distribution of all para-
meters was tested. Differences in continuous variables between groups
werecomparedusing theStudent t-test.Categorical variables arepresented
as numeric values and percentages. Correlative analyses were determined
by Spearman statistical test to determine the percentage of variance
explained or a spline fit for non-linear relationships. All statistical tests
were two-tailed and a P, 0.05 was considered statistically significant. Ana-
lyses were performedwithGraphPad PrismVersion 5 (GraphPad Software
Inc., SanDiego,CA,USA)andSPSSVersion21(IBMCorporation,NY,USA).
Results
Acute myocardial infarction results
in a peripheral monocytosis at 48 h
Following AMI in the mouse there was an increase (4-fold; P, 0.001)
in total peripheral circulatingmonocytes at 48 h (Figure 1A andB). Simi-
larly, inhumans,flowcytometryofwholeblood48 h followingonsetof
symptoms showed a 2-fold increase (P, 0.001) in total circulating
monocytes in comparisons with both (i) the hyperacute time point
and (ii) stable control subjects (Figure 1D–F). There was no significant
difference in total peripheral circulating monocytes at presentation
(hyperacute time point) compared with stable controls (Figure 1E).
Monocytes display an inflammatory
phenotype48h following acutemyocardial
infarction
In the mouse model of AMI at 48 h, monocytes were predominantly
of the Ly6Chi, inflammatory subset (P ¼ 0.005, Figure 1C). Similarly,
in human patients there was a small, but statistically significant,
CD14++CD162 inflammatory subset preponderance at 48 h
(82.9+6.9% vs. 75.9+ 5.1% (P, 0.001), compared with control
patients with stable atherosclerosis (Figure 1G).
The magnitude of the monocyte response
in both mice and humans correlates with
the extent of myocardial injury
Due to the anticipated marked variation in infarct size in mice that
underwent AMI, micewere analysed by tertiles of infarct size, as char-
acterizedbyTTE (Figure2A). The total peripheralmonocyte countwas
highly correlated with size of infarct (r2 ¼ 0.72, P, 0.001, Figure 2C).
Similarly, in humans, themagnitudeof themonocyte response foreach
patient (the difference between the 48 h monocyte count and the
hyperacute monocyte count) following AMI correlated with the
extent of irreversible myocardial injury determined by LGE at 6
months (r2 ¼ 0.42, P ¼ 0.001, Figure 2D) and weakly with the
volume of acute ischaemia, as measured by oedema on T2-weighted
magnetic resonance imaging (r2 ¼ 0.29, P ¼ 0.021; Figure 2E).
Having confirmed similarities in the elevation of monocyte sub-
types acutely after myocardial infarction, we next sought to evaluate
functional characteristics, as evidenced by alterations in patterns of
gene expression.
Gene expression profiling of peripheral
circulating monocytes identifies
differentially expressed genes in mice and
humans
Unsupervised principal components analysis demonstrated a clear
difference in groups in mice (Supplementary material online, Figure
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S1A). A similar effect was present in human subjects, though, as
expected, due to the variability in infarct size, ischaemic territory, is-
chaemia time, and genetic heterogeneity, the group effect was less
pronounced (Supplementary material online, Figure S1B).
Supervised analysis of the transcriptome at baseline in comparison
with 48 h following AMI in mousemonocytes revealed differential ex-
pression of 196 genes (fold change.2; P, 0.01) of which 168 genes
were significantly up-regulated and 28 genes were significantly
Figure 1 Acute myocardial infarction results in an increase in total peripheral circulating monocytes of an inflammatory phenotype in both mice
and humans. (A) Fluorescence-activate cell sorting (FACS) gating strategy to identify monocytes in peripheral blood (mice, n ¼ 6/group). (B) Acute
myocardial infarction results in a significant 4-fold increase in total monocytes (P, 0.001), which were predominately of an inflammatory Ly6Chi
phenotype (C). (D) Human monocyte (and monocyte subset) gating strategy (n ¼ 24 control group, n ¼ 30 acute myocardial infarction group).
(E)Acutemyocardial infarction results in a significant 2-fold increase in totalmonocytes (P, 0.001) at 48 h following injury but not at thehyperacute
(at presentation) timepoint (F ). (G)Monocytes at both the hyperacute and 48 h time points exhibited an inflammatoryCD14++CD162 phenotype.
Data are represented by mean+ standard deviation.
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down-regulated (Figure 3A). A similar comparison in humans identified
that 122 genes were differentially expressed (fold change .2;
P, 0.01), of which 72 genes were significantly up-regulated and
50 genes were significantly down-regulated (Figure 3B). The change in
gene expression was confirmed by PCR in selected genes in both mice
and human studies (Supplementary material online, Figures S2 and S3).
Figure 2 The extent of the monocyte response correlates with the extent of myocardial injury. (A) Transthoracic echocardiography of mouse
hearts following acute myocardial infarction (n ¼ 6/group). (B) Cardiac magnetic resonance imaging to quantify area of injury (T2-weighted se-
quence) and infarction (LGE sequence) in humans (n ¼ 30 acute timepoint, n ¼ 23 follow up). (C) In mice, the total peripheral monocyte count
was highly correlated with size of infarct (r2 ¼ 0.72, P, 0.001). (D) In humans, the magnitude of the monocyte response for each patient following
acute myocardial infarction correlated with the extent of irreversible myocardial injury determined by LGE at 6 months (r2 ¼ 0.42, P ¼ 0.001) and
weakly (non-linear relationship) with the area of risk, as measured by oedema (r2 ¼ 0.29, P ¼ 0.021, E).
Figure 3 Acute myocardial infarction results in differential expression of genes in circulatingmonocytes in both humans andmice. (A) Analysis of
the transciptome inmousemonocytes revealeddifferential expressionof196genes (fold change.2;P, 0.01)ofwhich168geneswere significantly
up-regulatedand28geneswere significantly down-regulated (n ¼ 6/group). (B) Inhumans, 122genesweredifferentiallyexpressed (fold change. 2;
P, 0.01) of which 72 genes were significantly up-regulated and 50 genes were significantly down-regulated (n ¼ 24, control group, n ¼ 30,
AMI group).
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Monocyte transcriptional response
in acutemyocardial infarction is conserved
in mice and humans
Having identified individual genes that were significantly differentially
expressed following AMI in peripheral circulating monocytes, we
then investigated whether these observed changes conformed
to similar patterns inmice and humans. In order to do this, we gener-
ated two ranked gene ‘signatures’ (n ¼ 200 genes) of the most
up-regulated genes in circulating monocytes following AMI, one in
the mouse model and one in humans. Gene set enrichment analysis
revealed significant enrichment of the mouse signature in the
ranked list of genes up-regulated in human monocytes after AMI
(P, 0.001, FDR , 0.001, Figure 4A). Similarly, a signature of genes
differentially expressed in humans revealed significant enrichment
in the ranked list of genes up-regulated in mouse monocytes after
AMI (P, 0.001, FDR , 0.01, Figure 4A). This comparison of the
primary data sets shows that the pattern of gene expression
induced in monocytes following myocardial infarction is significantly
conserved between species.
We then identified the biological processes present in human
and mouse monocytes following AMI by testing each monocyte
expressed dataset for up-regulation of a curated compendium of
2000 immune-related signatures.28 We identified 163 gene sets
that were enriched in both species following AMI, including gene
sets related to myeloid lineage, bacterial infection, and cytokine
stimulation of innate cells (Figure 4B and C ).
We next examined the representation of genes that lay in the
leading edges of gene sets showing enrichment in both species. The
leading-edge genesof anenriched gene set are those that contributed
most significantly to the enrichment score, and reflect the major
‘drivers’ of enrichment. The leading-edge genes showed striking simi-
larity between the two species (Figure 4D), again suggesting that the
transcriptional profile of monocytes following AMI in human and
mouse shared common biological characteristics. Several of the
most commonly represented genes in both human and mouse
included CD14, LGALS1, ITGAM, CD163, IFNGR1, CYBB, and TLR2
with roles inmonocyte inflammation, cell-to-cell signalling, and cellu-
lar proliferation (Figure 4D).
Gene set enrichment analysis identifies
functional characteristics of circulating
monocytes in acute myocardial infarction
To gain further insights into the biological function revealed by these
enrichments, we performed leading-edge analysis of themost signifi-
cantly enriched gene sets (FDR, 0.01) corresponding to the most
differentially expressed genes in mouse monocytes, following myo-
cardial infarction.We found twoclusters of genes (vertical clustering)
that were represented in multiple immune gene sets (horizontal
clustering) following AMI. This suggests that these genes form part
of transcriptional modules of coordinately regulated genes that
are up-regulated in mouse monocytes. We functionally annotated
these clusters of up-regulated genes using Gene Ontology (Figure 5),
and found significant over-representation of genes related to inflam-
mation (including TLR2, integrins, and chemokines including CCR1;
Supplementary material online, Tables S3 and S4) and cell cycle
(including cyclins, annexins, and tetraspanins; Supplementary mater-
ial online, Tables S5 and S6).
Validation of transcriptional findings
Up-regulation of proliferation-associated genes was a prominent
feature of the transcriptional profile of monocytes following AMI in
both humans and mice. To confirm this finding, we undertook
fluorescence-activate cell sorting (FACS) analysis of peripheral
blood mononuclear cells stored from the same patients at the 48 h
time point for the proliferation markers (Ki67 and cyclin) and
markers of inflammation (TLR-2 and TLR-4). As predicted from
the leading-edge analysis, there was (i) a significant increase in
TLR-2 at protein level (P, 0.001, Figure 6A), and (ii) no change in
TLR4 (P ¼ 0.14, Figure 6B). Ki67, a marker of cell proliferation, was
increased by 70% (P, 0.001, Figure 6C) in monocytes 48 h after
MI. Given the elevation in Ki67 in peripheral monocytes, we next
analysed mouse hearts to establish whether monocyte-derived
cells in the myocardium at this very early time point already showed
evidence of proliferation. In sham-treated mice, there were small
numbers of CD11b+ cells of which virtually none were Ki67+.
Following AMI in mice, there was a massive (130-fold), increase in
the number of CD11b+ cells within the myocardium, with abundant
Ki67-expressing CD11b+ leukocytes (P, 0.001 vs. sham-operated
hearts, Figure 6D and E).
Discussion
Data from mouse models strongly implicate the innate immune
system, and in particular monocytes as critical to initial inflammatory
and latter reparative processes following AMI.2,4–7 There is an early
influx of Ly6chi monocytes, which are inflammatory,15 with a later
preponderance of Ly6clow, F4/80high macrophages, which contribute
to myocardial repair.3 The relatively sparse data from human studies
in the context of AMI are consistent with these findings,14 but ana-
lyses have been confined to a small number of cell surface markers
that provide limited insight into function and are not biologically
useful.9,10
Whilst previous studies have investigated themonocyte transcrip-
tome, these have been limited to cells in the resting state.15,34 Here
we present analyses of the changes in the bloodmonocyte transcrip-
tome in mice and humans early after AMI. Through analysis of the
changes in patterns of gene expression, we have been able to gain
further functional insights into monocyte biology and this work con-
tributes twopotentially important findings. Firstly, the transcriptional
response following AMI in monocytes between mice and humans
appears to be largely conserved. This provides a validation of
mouse models to study innate immune responses following acute
MI. This is important since conservation across species cannot be
assumed. For instance, recent comparisons of changes in gene ex-
pression in models of sepsis showed differences in gene expression
between humans andmousemodels. Secondly, current thinking sug-
gests that monocytes act in ‘response mode’ whereby monocytes
enter the circulation and ‘patrol the vasculature. . .. before being
recruited to sites of inflammation.’.35 Although the absolute
number and proportion of Ly6chi monocytes in circulating blood is
well known to increase in AMI, changes in their function, implying a
form of ‘programming’ prior to arrival at the site of inflammation
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Figure 4 Monocytes from myocardial infarction in mouse and human are transcriptionally similar. (A) Mouse monocyte gene signature in acute
myocardial infarction strongly enriches in the ranked gene list of human bloodmonocytes 48 h following infarct comparedwith the stable state (left)
and vice versa (right). (B) Overlap of genes in same top enriching gene sets with the ranked gene list of the infarct vs. baseline state of monocytes in
human (left) and mouse (right). (C) Number of gene sets in ImmuneSigDB v1.0 strongly enriching (FDR , 0.01) in infarct human and/or mouse
monocytes. (D) Representation of genes in the leading edges of the 163 shared enriched gene sets. Genes were ranked from most to least repre-
sented inhumandataset and shown is thenumberof times that gene appears in the leadingedgeof the enrichedgene sets. Similarityof genesenriching
in leading edges of enriched gene sets in both organisms was assessed by Spearman correlation.
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have not previously been demonstrated. Here we show that, in mice
and human monocytes, patterns of gene expression associated with
inflammation and proliferation are switched on prior to their infiltra-
tion of injured tissue.
Whilst monocytes might be programmed in the blood, the recent
observation that a cardiosplenic axis exists in humans14 (supporting
findings in experimental models15) suggests that these cells could
also be programmed in a different pool and ‘released’ in response
to injury. Of relevance to this concept, observations from platelet
studies have demonstrated that the expression of MRP-14 was
found to be significantly up-regulated in circulating platelets of
patients prior to myocardial infarction.36 Our work therefore sug-
gests that a ‘pre-programmed state’ may not just be limited to plate-
lets but may also extend to monocytes.
Whilst our data do not exclude the possibility that naı¨ve mono-
cytes are recruited and thenactivated in themyocardiumand reintro-
duced into the blood, this is not likely given what is already known of
(i) the timing and (ii) large net flux ofmonocytes from spleen to heart
in AMI. Furthermore, recent studies in experimental models show
that once in the infarcted myocardium, Ly6chi monocytes differenti-
ate in situ into Ly6chi, F4/80+ macrophages.3,37
In keepingwithprevious reports,we show thatAMI leads to a small
but statistically significant increase in the number of Ly6chigh mono-
cytes. However, it is notable that in both the resting state and after
AMI, Ly6chigh monocytes predominate. Consequently, analysis of
Ly6chigh monocyte numbers provides virtually no functional insight.
We therefore undertook whole transcriptome analyses, using a
non-selective, unbiased approach that was not constrained by exam-
ination of one or other monocyte subsets. Better to understand
changes in gene expression, we employed GSEA. Gene set enrich-
ment analysis features a number of advantages when compared
with single-gene methods. Firstly, it provides a structure for inter-
pretationby identifyingpathwaysandprocesses.Rather than focusing
on highly regulated single genes (which can be difficult to interpret
mechanistically), GSEA focuses on gene sets, which tend to be
more reproducible and more interpretable. Secondly, when the
members of a gene set exhibit strong cross-correlation, GSEA
boosts signal-to-noise ratio making it possible to appreciate the con-
tributions of even modest changes in individual genes. Thirdly,
‘leading-edge analysis’ can help define gene subsets to elucidate key
players and identify critical biological processes.28
In the first instance, we show conservation between the mouse
andhumanmonocyte response toAMI. This is important since it pro-
vides surety for mechanistic studies in mice and for the development
of new therapies. There were, however, also differences between
species, with some biological processes (e.g. complement activation)
up-regulated in the mouse but not in humans. Identification of inter-
species differences is also important since they may anticipate
discrepant outcomes associated with targeting particular process,
including the complement cascade in clinical studies.38 Conversely,
we also identified pathways, e.g. integrin-linked kinase pathway that
has roles in cell migration, adhesion, and signalling,39 which have
not been described previously in this pathology possibly due to a
lack of function in this setting in mice.
Leading-edge analysis identified single genes CD14, LGALS1,
ITGAM, CD163, IFNGR1, CYBB, and TLR2 with roles in inflammation
and cellular proliferation as central biological processes to themono-
cyte response to AMI in humans. Cellular proliferation within target
Figure5 Leading-edge analysis identifies inflammation and cell cycling as novel biological states underlying themonocyte response to acutemyo-
cardial infarction. Leading-edge analysis of most significantly enriching gene sets (FDR , 0.01) in mousemonocytes followingmyocardial infarction
reveals metagenes involved in inflammatory and cell cycle processes. Representative genes in thesemetagenes are listed in Supplementary material
online, Table.
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tissue has recently, and unexpectedly, been shown to be critical to
monocyte mediated reparative processes following AMI in experi-
mental models3 and in atherosclerotic plaque progression40 and
thus might represent drug-sensitive targets.
Gene expression profiling methods have provided a clearer view
of the level of molecular heterogeneity that underlies pathologies in-
cluding cancer,41 cardiomyopathy,42 cardiac transplantation,43 vac-
cine development44 and in the diagnosis of giant cell myocarditis.45
These technologies have also been used in the identification of
novel targets for drug development46 and in predicting response to
treatment.47 By applying these methodologies to the setting of
AMI, we have identified a number of biological pathways that
are up-regulated in monocytes following AMI in both mice and
humans. The specific targeting of immune cells in AMI is an attractive
therapeutic option; however, clinical trials that have adopted a broad
strategy of inhibiting inflammation have been disappointing to
date.48,49 Targeted therapies based on patient stratification on the
basis of target cell transcriptome is appealing, identifying patients
who have most to gain from specific biological therapies and those
that would only be subjected to undue risk.
Limitations
Although the gene sets were obtained from large compendia
of published data, they are inevitably incomplete in terms of the
totality of possible biological states and also biased by the focus of ex-
perimental data submitted. Therefore, the interpretations of the
transcriptome should be judged in that context and not considered
definitive. It is also unlikely that the monocyte transcriptome is
static, changes will occur over time, perhaps in response to new
signals, and thus the peripheral monocyte transcriptome may not
necessarily reflect the transcriptome following infiltration into is-
chaemic myocardium.
This investigation was undertaken at a single time point, in part
informed by the data for mice in the literature, although observed
changes may vary between species at different timepoints. Subse-
quent studies will extend current evaluations to later timepoints.
The magnitude of the monocyte response correlated with extent
of LGE at 6 months but only weakly with early myocardial oedema.
This may reflect a monocyte response that is driven by the extent
of tissue that has undergone irreversible injury. However, a recent
study has shown a biphasic accumulation of myocardial oedema
that diminishes the utility of a single measurement to indicate
extent of acute ischemic injury.50
Conclusions
This study demonstrates that the peripheral blood monocyte
response following AMI is conserved between species both
Figure 6 Inflammatory and mitosis pathways are up-regulated in circulating monocytes en route to inflamed myocardium. (A) Flow cytometry of
peripheral circulating monocytes 48 h following acute myocardial infarction in humans identified a significant increase in the expression of TLR2
(P, 0.001) but not TLR4 (P ¼ 0.14, B) (n ¼ 12/group). (C) Ki67 expression was significantly up-regulated in monocytes at 48 h following injury
but not hyperacutely (at presentation) in comparison with controls (P, 0.001) (n ¼ 12/group). (D and E) Immunohistochemistry of mouse
hearts (blue: DAPI, red: CD11b, green Ki67) following acute myocardial infarction confirmed a significant increase in the number of leukocytes
expressing Ki67 (white arrows) (P, 0.001) indicating up-regulation of mitosis pathways in infarcted myocardium (n ¼ 3/group). Data are repre-
sented by mean+ standard deviation.
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phenotypically but also at the level of the transcriptome. We show
that circulating monocytes are ‘programmed’ with a number of bio-
logical processesup-regulatedprior to their arrival at sitesofmyocar-
dial injury and have identified mitosis a particularly important, but
little recognized contributor to early inflammation and possibly
latter reparative processes. Although monocyte proliferation has
recently been shown to be important several days after AMI in
mice,3 our data suggest both pre-activation and early proliferation
at the site of infarction.
Supplementary material
Supplementary material is available at European Heart Journal online.
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